Table 1. Clinicopathological characteristics in breast cancer patients with Ano1 expression.
| No. of Cases | % | |
|---|---|---|
| Total no. | 395 | 100 |
| Median age [range], years | 51[20–82] | |
| Age (years) | ||
| <51 | 210 | 53.2 |
| ≥51 | 185 | 46.8 |
| Sex | ||
| Female | 395 | 100.0 |
| Menopausal status | ||
| Premenopausal | 205 | 51.9 |
| Postmenopausal | 190 | 48.1 |
| First-degree family history of breast cancer | ||
| No | 332 | 84.1 |
| Yes | 63 | 15.9 |
| Tumor size (cm) | ||
| ≤ 2.0 | 134 | 33.9 |
| <2 ~<5 | 201 | 50.9 |
| ≥5.0 | 60 | 15.2 |
| Histological grade | ||
| Grade 1 | 45 | 11.4 |
| Grade 2 | 314 | 79.5 |
| Grade 3 | 36 | 9.1 |
| Clinical stages | ||
| I or II | 281 | 71.1 |
| IIIA~IIIC | 114 | 28.9 |
| Lymph node metastasis | ||
| Node-negative | 194 | 49.1 |
| Node-positive | 201 | 50.9 |
| ER status | ||
| Negative | 127 | 32.2 |
| Positive | 268 | 67.8 |
| PR status | ||
| Negative | 129 | 32.7 |
| Positive | 266 | 67.3 |
| HER2 status | ||
| Negative | 167 | 42.3 |
| Positive | 228 | 57.7 |
| Triple negative status | ||
| Non-triple negative | 364 | 92.2 |
| Triple negative | 31 | 7.8 |
| Tamoxifen treatment | ||
| No | 90 | 22.8 |
| Yes | 305 | 77.2 |
| Postoperative therapeutic regimens | ||
| Anthracycline alone or combined with paclitaxel | 348 | 88.1 |
| Other chemotherapies or treatments † | 47 | 11.9 |
Abbreviations: ER, Estrogen receptor; PR, Progesterone rec66eptor; HER2, Human epidermal growth factor receptor.
†Other chemotherapies included paclitaxel alone (n = 21), NP regimen (navelbine plus cisplatin, n = 15), TP regimen (Docetaxel plus cisplatin, n = 11).